Your browser doesn't support javascript.
loading
Long-term results and safety of fibroblast growth factor injection for unilateral vocal fold paralysis.
Yamauchi, Tomohiko; Kanazawa, Takeharu; Hasegawa, Tomohiro; Kurakami, Kazuya; Konomi, Ujimoto; Hirosaki, Mayu; Komazawa, Daigo; Nozawa, Miki; Takahashi, Satoka; Watanabe, Yusuke.
Afiliación
  • Yamauchi T; Division of Laryngeal Surgery, Department of Otolaryngology-Head and Neck Surgery Jichi Medical University Shimotsuke Japan.
  • Kanazawa T; Division of Laryngeal Surgery, Department of Otolaryngology-Head and Neck Surgery Jichi Medical University Shimotsuke Japan.
  • Hasegawa T; Tokyo Voice Center International University of Health and Welfare Tokyo Japan.
  • Kurakami K; Tokyo Voice Center International University of Health and Welfare Tokyo Japan.
  • Konomi U; Tokyo Voice Center International University of Health and Welfare Tokyo Japan.
  • Hirosaki M; Department of Otolaryngology Head and Neck Surgery, Faculty of Medicine Yamagata University Yamagata Japan.
  • Komazawa D; Tokyo Voice Center International University of Health and Welfare Tokyo Japan.
  • Nozawa M; Voice and Dizziness Clinic Futakotamagawa Otolaryngology Tokyo Japan.
  • Takahashi S; Tokyo Voice Center International University of Health and Welfare Tokyo Japan.
  • Watanabe Y; Tokyo Voice Center International University of Health and Welfare Tokyo Japan.
Laryngoscope Investig Otolaryngol ; 7(3): 799-806, 2022 Jun.
Article en En | MEDLINE | ID: mdl-35734070
ABSTRACT

Objectives:

Treatments for unilateral vocal fold paralysis (UVFP) include conservative voice rehabilitation, vocal fold injection, and laryngeal framework surgery. We proposed basic fibroblast growth factor (bFGF) injection as a potential novel treatment for UVFP and have reported the short-term results. In this study, we present the long-term results and safety of vocal fold bFGF injection as a treatment for UVFP.

Methods:

This retrospective study included 42 patients (25 males and 17 females) with UVFP who were administered a local injection of bFGF. The injection regimen involved injecting FGF (0.5 µg/ml in 0.5 ml per side) into the bilateral vocal folds using a 23-gauge injection needle. Phonological outcomes were evaluated 6 months and 12 months after the injection.

Results:

Overall, 26 patients received a single injection of bFGF, six patients received an additional injection, and 10 patients received the additional framework surgery. Maximum phonation time, mean flow rate, pitch range, jitter and shimmer percentages, the total GRBAS (grade, roughness, breathiness, asthenia, strain) score, and voice handicap index scores improved significantly in the long term. In patients who received the additional injection or framework surgery, the effects of bFGF injection were temporary, but did not interfere with the performance of the framework surgery.

Conclusion:

In total, 42 patients who underwent vocal fold bFGF injections were reviewed. The bFGF injections were effective and safe in the long-term results for UVFP in the selected cases. Some patients with severe symptoms benefited from the additional framework surgery but not the additional bFGF injection.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Observational_studies Idioma: En Revista: Laryngoscope Investig Otolaryngol Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Observational_studies Idioma: En Revista: Laryngoscope Investig Otolaryngol Año: 2022 Tipo del documento: Article